---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-103157"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:25:32.833512+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Therapeutics announces 1-for-15 reverse stock split effective Sept 30

## Summary
- Board approved 1-for-15 reverse stock split on Sept 23, 2024; stockholders authorized at Sept 16 meeting.
- Reverse split effective at 11:59 p.m. ET on Sept 30, 2024; trading on split-adjusted basis Oct 1 under BCLI.
- No fractional shares issued; cash in lieu based on closing price prior to effective time.
- New CUSIP number 10501E 300; par value unchanged at $0.00005 per share.

## SEC filing metadata
- accession: 0001104659-24-103157
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465924103157/0001104659-24-103157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465924103157/tm2424656d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-103157
- JSON: https://secwatch.observer/filing/0001104659-24-103157.json
- Plain text: https://secwatch.observer/filing/0001104659-24-103157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.